Dual PI3 K/mTOR inhibition reduces prostate cancer bone engraftment altering tumor-induced bone remodeling
Morbidity in advanced prostate cancer patients is largely associated with bone metastatic events. The development of novel therapeutic strategies is imperative in order to effectively treat this incurable stage of the malignancy. In this context, Akt signaling pathway represents a promising therapeu...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2018-04-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428318771773 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849697652527071232 |
|---|---|
| author | Andrea Mancini Alessandro Colapietro Simona Pompili Andrea Del Fattore Simona Delle Monache Leda Assunta Biordi Adriano Angelucci Vincenzo Mattei Chris Liang Giovanni Luca Gravina Claudio Festuccia |
| author_facet | Andrea Mancini Alessandro Colapietro Simona Pompili Andrea Del Fattore Simona Delle Monache Leda Assunta Biordi Adriano Angelucci Vincenzo Mattei Chris Liang Giovanni Luca Gravina Claudio Festuccia |
| author_sort | Andrea Mancini |
| collection | DOAJ |
| description | Morbidity in advanced prostate cancer patients is largely associated with bone metastatic events. The development of novel therapeutic strategies is imperative in order to effectively treat this incurable stage of the malignancy. In this context, Akt signaling pathway represents a promising therapeutic target able to counteract biochemical recurrence and metastatic progression in prostate cancer. We explored the therapeutic potential of a novel dual PI3 K/mTOR inhibitor, X480, to inhibit tumor growth and bone colonization using different in vivo prostate cancer models including the subcutaneous injection of aggressive and bone metastatic (PC3) and non-bone metastatic (22rv1) cell lines and preclinical models known to generate bone lesions. We observed that X480 both inhibited the primary growth of subcutaneous tumors generated by PC3 and 22rv1 cells and reduced bone spreading of PCb2, a high osteotropic PC3 cell derivative. In metastatic bone, X480 inhibited significantly the growth and osteolytic activity of PC3 cells as observed by intratibial injection model. X480 also increased the bone disease-free survival compared to untreated animals. In vitro experiments demonstrated that X480 was effective in counteracting osteoclastogenesis whereas it stimulated osteoblast activity. Our report provides novel information on the potential activity of PI3 K/Akt inhibitors on the formation and progression of prostate cancer bone metastases and supports a biological rationale for the use of these inhibitors in castrate-resistant prostate cancer patients at high risk of developing clinically evident bone lesions. |
| format | Article |
| id | doaj-art-e445381756ff43f0a6a45e4c9d3fe13e |
| institution | DOAJ |
| issn | 1423-0380 |
| language | English |
| publishDate | 2018-04-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Tumor Biology |
| spelling | doaj-art-e445381756ff43f0a6a45e4c9d3fe13e2025-08-20T03:19:08ZengSAGE PublishingTumor Biology1423-03802018-04-014010.1177/1010428318771773Dual PI3 K/mTOR inhibition reduces prostate cancer bone engraftment altering tumor-induced bone remodelingAndrea Mancini0Alessandro Colapietro1Simona Pompili2Andrea Del Fattore3Simona Delle Monache4Leda Assunta Biordi5Adriano Angelucci6Vincenzo Mattei7Chris Liang8Giovanni Luca Gravina9Claudio Festuccia10Department of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L’Aquila, L’Aquila, ItalyDepartment of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L’Aquila, L’Aquila, ItalyDepartment of Biotechnological and Applied Clinical Sciences, Human Anatomy, University of L’Aquila, L’Aquila, ItalyBambino Gesù Children’s Hospital, Rome, ItalyDepartment of Biotechnological and Applied Clinical Sciences, Laboratory of Applied Biology, University of L’Aquila, L’Aquila, ItalyDepartment of Biotechnological and Applied Clinical Sciences, Laboratory of Experimental Oncology, University of L’Aquila, L’Aquila, ItalyDepartment of Biotechnological and Applied Clinical Sciences, Laboratory of General Pathology, University of L’Aquila, L’Aquila, ItalyLaboratory of Experimental Medicine and Environmental Pathology, Rieti University Hub “Sabina Universitas,” Rieti, ItalyXcovery LLC, West Palm Beach, FLDepartment of Biotechnological and Applied Clinical Sciences, Division of Radiology Oncology; University of L’Aquila, L’Aquila, ItalyDepartment of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L’Aquila, L’Aquila, ItalyMorbidity in advanced prostate cancer patients is largely associated with bone metastatic events. The development of novel therapeutic strategies is imperative in order to effectively treat this incurable stage of the malignancy. In this context, Akt signaling pathway represents a promising therapeutic target able to counteract biochemical recurrence and metastatic progression in prostate cancer. We explored the therapeutic potential of a novel dual PI3 K/mTOR inhibitor, X480, to inhibit tumor growth and bone colonization using different in vivo prostate cancer models including the subcutaneous injection of aggressive and bone metastatic (PC3) and non-bone metastatic (22rv1) cell lines and preclinical models known to generate bone lesions. We observed that X480 both inhibited the primary growth of subcutaneous tumors generated by PC3 and 22rv1 cells and reduced bone spreading of PCb2, a high osteotropic PC3 cell derivative. In metastatic bone, X480 inhibited significantly the growth and osteolytic activity of PC3 cells as observed by intratibial injection model. X480 also increased the bone disease-free survival compared to untreated animals. In vitro experiments demonstrated that X480 was effective in counteracting osteoclastogenesis whereas it stimulated osteoblast activity. Our report provides novel information on the potential activity of PI3 K/Akt inhibitors on the formation and progression of prostate cancer bone metastases and supports a biological rationale for the use of these inhibitors in castrate-resistant prostate cancer patients at high risk of developing clinically evident bone lesions.https://doi.org/10.1177/1010428318771773 |
| spellingShingle | Andrea Mancini Alessandro Colapietro Simona Pompili Andrea Del Fattore Simona Delle Monache Leda Assunta Biordi Adriano Angelucci Vincenzo Mattei Chris Liang Giovanni Luca Gravina Claudio Festuccia Dual PI3 K/mTOR inhibition reduces prostate cancer bone engraftment altering tumor-induced bone remodeling Tumor Biology |
| title | Dual PI3 K/mTOR inhibition reduces prostate cancer bone engraftment altering tumor-induced bone remodeling |
| title_full | Dual PI3 K/mTOR inhibition reduces prostate cancer bone engraftment altering tumor-induced bone remodeling |
| title_fullStr | Dual PI3 K/mTOR inhibition reduces prostate cancer bone engraftment altering tumor-induced bone remodeling |
| title_full_unstemmed | Dual PI3 K/mTOR inhibition reduces prostate cancer bone engraftment altering tumor-induced bone remodeling |
| title_short | Dual PI3 K/mTOR inhibition reduces prostate cancer bone engraftment altering tumor-induced bone remodeling |
| title_sort | dual pi3 k mtor inhibition reduces prostate cancer bone engraftment altering tumor induced bone remodeling |
| url | https://doi.org/10.1177/1010428318771773 |
| work_keys_str_mv | AT andreamancini dualpi3kmtorinhibitionreducesprostatecancerboneengraftmentalteringtumorinducedboneremodeling AT alessandrocolapietro dualpi3kmtorinhibitionreducesprostatecancerboneengraftmentalteringtumorinducedboneremodeling AT simonapompili dualpi3kmtorinhibitionreducesprostatecancerboneengraftmentalteringtumorinducedboneremodeling AT andreadelfattore dualpi3kmtorinhibitionreducesprostatecancerboneengraftmentalteringtumorinducedboneremodeling AT simonadellemonache dualpi3kmtorinhibitionreducesprostatecancerboneengraftmentalteringtumorinducedboneremodeling AT ledaassuntabiordi dualpi3kmtorinhibitionreducesprostatecancerboneengraftmentalteringtumorinducedboneremodeling AT adrianoangelucci dualpi3kmtorinhibitionreducesprostatecancerboneengraftmentalteringtumorinducedboneremodeling AT vincenzomattei dualpi3kmtorinhibitionreducesprostatecancerboneengraftmentalteringtumorinducedboneremodeling AT chrisliang dualpi3kmtorinhibitionreducesprostatecancerboneengraftmentalteringtumorinducedboneremodeling AT giovannilucagravina dualpi3kmtorinhibitionreducesprostatecancerboneengraftmentalteringtumorinducedboneremodeling AT claudiofestuccia dualpi3kmtorinhibitionreducesprostatecancerboneengraftmentalteringtumorinducedboneremodeling |